NCT05111509 - A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 22, 2022

Primary Completion Date

April 30, 2026

Study Completion Date

June 30, 2026

Conditions

Neuroendocrine Tumor Grade 2Neuroendocrine Tumor Grade 1

Interventions

DRUG

[203Pb]VMT-α-NET

3 to 5 miliCuries of \[203\]Pb administered intravenously 60 minutes before the start of the scans.

DEVICE

SPECT/CT

Scans are administered over 3 days: 1 hour post injection, 4 to 8 hours post-injection, 24 to 30 hours post-injection, and 42 to 52 hours post-injection.

Trial Locations (1)

52242

The University of Iowa, Iowa City